Roche Holding AG and partners Chugai Pharmaceutical Co., Ltd. and MorphoSys AG are anticipating data from their IgG1 antibody for Alzheimer’s disease (AD), gantenerumab.
The candidate targets amyloid beta, an approach that saw a recent resurgence of confidence after rival Eisai Co., Ltd....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?